MedTrace Logo

Everolimus and Temozolomide in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3)

NCT02248012 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2019-12-19

No results posted yet for this study

Summary

To study the efficacy of everolimus combined with temozolomide as first-line treatment in advanced gastroenteropancreatic neuroendocrine carcinoma with a Ki67 of 20-55%, measured as disease control rate (non-progressive disease) at 6 months.

Conditions

  • Neuroendocrine Carcinoma

Interventions

DRUG

Everolimus , temozolomide

Sponsors & Collaborators

  • Skane University Hospital

    collaborator OTHER

  • Copenhagen University Hospital, Denmark

    collaborator OTHER

  • Rigshospitalet, Denmark

    collaborator OTHER

  • Uppsala University Hospital

    collaborator OTHER

  • Aarhus University Hospital

    collaborator OTHER

  • Sahlgrenska University Hospital

    collaborator OTHER

  • Ullevaal University Hospital

    collaborator OTHER

  • Haukeland University Hospital

    lead OTHER

Principal Investigators

  • Halfdan Sorbye, MD · Haukeland Univ Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2018-01-31
Completion
2019-12-01

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02248012 on ClinicalTrials.gov